| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 18, 2020 |
Chief Commercial Officer
Trans History: 5
|
Chief Commercial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 120,000 |
| May 13, 2022 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 60,000 | $0.56 | 121,579 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 124,794 |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 144,794 |
| Mar 01, 2019 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 145,000 | -- | 145,000 |
| Jun 09, 2022 |
Director
Trans History: 18
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 164,422 | -- | 164,422 |
| Jun 09, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 164,422 | -- | 164,422 |
| Jun 09, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 164,422 | -- | 164,422 |
| Jun 09, 2022 |
Director
Trans History: 9
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 164,422 | -- | 164,422 |
| Jun 09, 2022 |
Director
Trans History: 3
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 164,422 | -- | 164,422 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.